Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin proline plus metformin for cognitive impairment in type 2 diabetes
ChiCTR2500113390Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of henagliflozin in type 2 diabetes mellitus (T2DM) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: MoCA Rating Scale Score. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on ChiCTR2500113390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113390.